How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and iboga...
Last updated: 2026-04-20 20:59:35 ET
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and iboga...
President Trump signed an executive order Saturday that eases restrictions on the research of the psychedelics including the drug ibogaine, which is u...
President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaineDonald Trump on Saturday announced reforms in...
Ibogaine is banned under the federal government's most restrictive category for illegal, high-risk drugs.
The executive order will open the door for more research into the psychedelic drug ibogaine, sources told CBS News earlier this week.
The president will direct federal agencies to boost research into the drugs and support clinical trials, moves championed by Robert F. Kennedy Jr.
Ibogaine is used in Mexico and the Caribbean to treat depression, anxiety, addiction and brain trauma.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE